I’m giving grand rounds on Tuesday on SGLT2 inhibitors and I’m trying to come up with a list of therapies that lower CV death in diabetes.
Here is my list:
- Blood pressure control
- Empagliflozen
- Canagliflozin
- CANVAS Only partial credit here. CV death was part of the composite outcome, but CVD was not significant on its own
- Semaglutide
- SUSTAIN-6 Weak. Hit the primary outcome but CV death was explicitly identical between groups
- Liraglutide
Drugs that have run the FDA CV disease gauntlet and that are non-inferior to standard of care:
- Exanatide
- Rosiglitazone
- Pioglitazone
- Alogliptin
- EXAMINE (This is a secondary prevention trial. As far as I can tell it is the only FDA mandated outcome trial that is specifically designed as a secondary prevention. Not sure why.)
- Saxagliptin
- Degludec
I’m sure I’m missing some. There must be a statin trial of diabetics. Right?
Swapnil was first with the statin answer:
Cites 7-9 from https://t.co/nlIqGSAso3 seem to be statin in DM RCTs pic.twitter.com/KVwu0aKC2A
— Swapnil Hiremath @hswapnil@bsky.social (@hswapnil) December 3, 2017
And Edgar came up with a great visual from a review paper:
Completed and ongoing CV outcome trials in Type 2 Diabetes #Nephpearls
👉🏼 https://t.co/Ez2eNLUrlR pic.twitter.com/y09I8B8JQU— Edgar V. Lerma 🇵🇭 (@edgarvlermamd) December 3, 2017
And Szymon came up with the Steno trial. I can’t believe I forgot about that one.
Multifactorial intervention in DM2 https://t.co/Xyd9f7Bwg4 STENO-2 Trial pic.twitter.com/QImGBS0Srx
— Szymon Brzósko (@brzoskos) December 3, 2017